Chronic Obstructive Pulmonary Disease (COPD): Seven-Market Drug Forecast and Market Analysis - Update (2025)

1.1 Summary of Changes
1.2 Executive Summary
1.3 The COPD market will show steady growth during the forecast period, reaching sales of $30.2 billion in 2033
1.4 GSK, AstraZeneca, and Sanofi/Regeneron competing for first place in 2033
1.5 COPD remains a market with high unmet need
1.6 Lack of established biomarkers for COPD
1.7 Late-stage COPD pipeline therapies to target a niche population
1.8 What do physicians think?

2.1 Catalyst
2.2 Summary of Changes
2.3 Related reports
2.4 Upcoming related reports

3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 2016 GOLD classification or staging systems
3.3 New 2023 GOLD classification system
3.3.1 US key opinion leader insights
3.3.2 EU key opinion leader insights
3.3.3 Japan key opinion leader insights
3.4 Symptoms
3.5 Asthma-COPD overlap
3.5.1 Definition of asthma-COPD overlap
3.5.2 Etiology and pathophysiology
3.5.3 Key opinion leader insights on asthma-COPD overlap

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumptions and methods: total prevalent cases of COPD - 7MM
4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of COPD
4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of COPD by severity - GOLD 2016 criteria using mMRC score
4.4.6 Forecast assumptions and methods: diagnosed prevalent cases of COPD by severity - GOLD 2016 criteria using CAT score
4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of COPD by severity - GOLD 2023 criteria using mMRC/CAT scores
4.5 Epidemiological forecast for COPD
4.5.1 Total prevalent cases of COPD
4.5.2 Diagnosed prevalent cases of COPD
4.5.3 Age-specific diagnosed prevalent cases of COPD
4.5.4 Sex-specific diagnosed prevalent cases of COPD
4.5.5 Diagnosed prevalent cases of COPD by GOLD 2016 criteria using mMRC score
4.5.6 Diagnosed prevalent cases of COPD by GOLD 2016 criteria using CAT score
4.5.7 Diagnosed prevalent cases of COPD by GOLD 2023 criteria using mMRC score
4.5.8 Diagnosed prevalent cases of COPD by GOLD 2023 criteria using CAT score
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis

5.1 Diagnosis and treatment overview
5.2 US
5.3 EU
5.4 Japan

6.1 Overview

7.1 Overview
7.2 Disease-modifying treatments to reverse the progression of COPD
7.3 Lack of access and training of spirometry
7.4 Biomarkers for COPD
7.5 Improved clinical trial design
7.6 Earlier diagnosis and recognition

8.1 Overview
8.1.1 Focus on type 2 inflammation with biologics
8.1.2 Focus on treatment of exacerbators
8.1.3 Targeted Biologic Therapies for Inflammatory Endotypes
8.2 Clinical trials design
8.2.1 Defining the primary endpoints
8.2.2 Innovative trial design
8.2.3 Phenotyping in COPD trials

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - key opinion leaders interviewed for this report
13.4.1 Key opinion leaders
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Managing Epidemiologist
13.6.5 Vice President of Disease Intelligence and Epidemiology
13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

Table 1 Summary of Changes of COPD: Seven- Market Drug Forecast and Analysis Report
Table 2: COPD - Key metrics in the 7MM
Table 3: GOLD criteria for the classification of COPD, 2018
Table 4: Symptoms of COPD
Table 5: Modified mMRC Dyspnea Scale
Table 6: Risk factors and comorbidities for COPD
Table 7 Treatment guidelines for COPD
Table 8 Country profile - US, 2023
Table 9 Region profile - 5EU, 2023
Table 10 Country profile - Japan, 2023
Table 11: Top deals by value, 2019-24
Table 12: COPD market - global drivers and barriers, 2023-2033
Table 13: Key events impacting sales for COPD in the US, 2023-2033
Table 14: COPD market - drivers and barriers in the US, 2023-2033
Table 15: Key events impacting sales for COPD in the 5EU, 2023-2033
Table 16: COPD market - drivers and barriers in the 5EU, 2023-2033
Table 17: Key events impacting sales for COPD in Japan, 2023-2033
Table 18: COPD market - drivers and barriers in Japan, 2023-2033
Table 19: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for COPD in 2023 and 2033
Figure 2: Analysis of the company portfolio gap in COPD during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that the analyst expects to be licensed for the treatment of COPD during the forecast period
Figure 4: Normal lungs and lungs with COPD
Figure 5: The pathogenesis of COPD
Figure 6: 2023 GOLD classification and segmentation of COPD patients
Figure 7: 7MM, total prevalence of COPD (%), men and women, ages =35 years, 2023
Figure 8: 7MM, diagnosed prevalence of COPD (%), men and women, ages =35 years, 2023
Figure 9: 7MM, sources used and not used to forecast the total prevalent cases of COPD
Figure 10: 7MM, sources used and not used to forecast the diagnosed prevalent cases of COPD
Figure 11: 7MM, sources used and not used to forecast the diagnosed prevalent cases of COPD by severity - GOLD 2016 criteria using mMRC score
Figure 12: 7MM, sources used and not used to forecast the diagnosed prevalent cases of COPD by severity - GOLD 2016 criteria using CAT score
Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of COPD by severity - GOLD 2023 criteria using mMRC or CAT scores
Figure 14: 7MM, total prevalent cases of COPD, N, both sexes, ages =35 years, 2023
Figure 15: 7MM, diagnosed prevalent cases of COPD, N, both sexes, ages =35 years, 2023
Figure 16: 7MM, diagnosed prevalent cases of COPD by age, N, both sexes, 2023
Figure 17: 7MM, diagnosed prevalent cases of COPD by sex, N, ages =35 years, 2023
Figure 18: 7MM, diagnosed prevalent cases of COPD by GOLD 2016 criteria using mMRC score, N, both sexes, ages =35 years, 2023
Figure 19: 7MM, diagnosed prevalent cases of COPD by GOLD 2016 criteria using CAT score, N, both sexes, ages =35 years, 2023
Figure 20: 7MM, diagnosed prevalent cases of COPD by GOLD 2023 criteria using mMRC score, N, both sexes, ages =35 years, 2023
Figure 21: 7MM, diagnosed prevalent cases of COPD by GOLD 2023 criteria using CAT score, N, both sexes, ages =35 years, 2023
Figure 22: COPD initial treatment algorithm according to 2023 GOLD guidelines
Figure 23: Pharmacological treatment of COPD patients in the follow-up algorithm
Figure 24: Unmet needs and opportunities in COPD
Figure 25: Overview of the development pipeline in COPD
Figure 26: Key Phase II/III trials for promising pipeline agents
Figure 27: Competitive assessment of the marketed and pipeline small molecules benchmarked against Roflumilast
Figure 28: Competitive assessment of the marketed and pipeline biologics benchmarked against Dupixent
Figure 29: Analysis of the company portfolio gap in COPD during the forecast period
Figure 30: Global (7MM) sales forecast by country for COPD in 2023 and 2033
Figure 31: Sales forecast by class for COPD in the US, 2023 and 2033
Figure 32: Sales forecast by class for COPD in the 5EU, 2023 and 2033
Figure 33: Sales forecast by class for COPD in Japan, 2023 and 2033